- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06485908
Axitinib ed etoposide metronomico orale per bambini pediatrici e medulloblastoma ed ependimoma refrattari/recidivanti AYA (MEPENDAX)
MEPENDAX: studio di fase I/II su axitinib (Inlyta®) ed etoposide metronomico orale per bambini pediatrici e medulloblastoma ed ependimoma refrattari/recidivanti AYA
It is an open multicentric phase I/II trial with axitinib (Inlyta®) and metronomic delivery of etoposide for children, adolescent and young adults (AYA) with refractory/ relapsing solid tumors. It is a two-stage trial:
First stage: To determine the Maximum Tolerated Dose (MTD) of the combination of axitinib and oral metronomic etoposide for patient with medulloblastoma or ependymoma Second stage: Extension cohort evaluating the preliminary efficacy at the recommended dose for the phase II (RDP2) of the combination. The 2nd stage will start after a meeting of independent data monitoring committee (IDMC). Two cohorts of 9 patients with ependymoma and medulloblastoma Patients treated at first stage won't be included in the second stage.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: Nicolas ANDRE
- Numero di telefono: 0491386792
- Email: nicolas.andre@ap-hm.fr
Backup dei contatti dello studio
- Nome: Franceline CARTIER
- Email: franceline.cartier@ap-hm.fr ; promotion.interne@ap-hm.fr
Luoghi di studio
-
-
-
Angers, Francia
- Reclutamento
- Centre Hospitalier Universitaire D'Angers
-
Contatto:
- BRISSET
- Numero di telefono: 0241356524
- Email: claire.brisset@chu-angers.fr
-
Bordeaux, Francia
- Reclutamento
- Centre Hospitalier Universitaire De Bordeaux
-
Contatto:
- ICHER
- Numero di telefono: 0557820448
- Email: celine.icher@chu-bordeaux.fr
-
Lyon, Francia
- Reclutamento
- IHOPe Institut d'Hématologie et d'Oncologie Pédiatrique
-
Contatto:
- LEBLOND
- Numero di telefono: 0469166550
- Email: pierre.leblond@ihope.fr
-
Marseille, Francia
- Reclutamento
- Assistance Publique - Hôpitaux de Marseille
-
Contatto:
- Nicolas Andre
- Numero di telefono: +330491386821
- Email: nicolas.andre@ap-hm.fr
-
Nancy, Francia
- Reclutamento
- CHRU De Nancy
-
Contatto:
- Marie-Sophie MERLIN
- Numero di telefono: +33 0383154734
- Email: m.merlin@chru-nancy.fr
-
Paris, Francia
- Reclutamento
- Institut Curie
-
Contatto:
- LERUSTE
- Numero di telefono: 0144324015
- Email: amaury.lereuste@curie.fr
-
Strasbourg, Francia
- Reclutamento
- Les Hopitaux Universitaires De Strasbourg
-
Contatto:
- Natacha ENTZ-WERLE
- Numero di telefono: +33 0388128097
- Email: natacha.entz-werle@chru-strasbourg.fr
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Histologically proven diagnosis of ependymoma or medulloblastoma
- Methyloma classification performed or available material for methyloma analysis
- Confirmed progressive or refractory disease despite standard therapy, or for which no effective standard therapy exists
- Male and female subjects with > 4 to ≤ 25 years of age at inclusion
- Weight > 20 kg
- Evaluable target lesion(s) according to RAPNO
- Performance status: Karnofsky performance status (for patients >12 years of age) or Lansky Play score (for patients ≤12 years of age) ≥ 70%. Patients who are unable to walk because of paralysis or stable neurological disability, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
- Life expectancy ≥ 3 months
- No known allergy to any of the compounds in the experimental treatment
- Able to take oral treatments
- Adequate organ function:
Hematologic criteria
- Peripheral absolute neutrophil count (ANC) ≥ 1000/mm3 (unsupported)
- Platelet count ≥ 100,000/mm3 (unsupported)
- Hemoglobin ≥ 8.0 g/dL (transfusion is allowed) Cardiac function
- Shortening fraction (SF) >29% and left ventricular ejection fraction (LVEF) ≥50% at baseline, as determined by echocardiography (mandatory only for patients who have received cardiotoxic therapy).
Renal and hepatic function
-
Serum creatinine < 1.5 x upper limit of normal (ULN) for age
-
Total bilirubin < 1.5 x ULN
-
Alanine aminotransferase (ALT)/ Aspartate aminotransferase (AST)/ < 2.5 x ULN
- Able to comply with scheduled follow-up and with management of toxicity.
- Females of child bearing potential must have a negative serum pregnancy test within 7 days prior to initiation of treatment.
- Sexually active patients must agree to use adequate and appropriate contraception (in accordance with Clinical Trials Facilitation and Coordination Group (CTFG) recommendations) while on study drug and for 6 months after stopping the study drug.
- Patient able to comfortably swallow capsules.
- Written informed consent from parents/legal representative, patient, and age-appropriate assent before any study-specific screening procedures are conducted according to local, regional or national guidelines.
- Patient affiliated to a social security regimen or beneficiary of the same according to local requirements.
Non-inclusion Criteria
- Chemotherapy within 21 days of day 1 from the start of study treatment. This period can be shortened in the case of treatment with vincristine (2 weeks) and extended to 6 weeks in the case of treatment with nitrosureas. The period is set to 5 half-lives in the case of targeted therapies or metronomic chemotherapy. The period is set to 2 weeks after bevacizumab administration. Evidence of > Grade 1 recent CNS hemorrhage on the baseline MRI or scan.
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter drug absorption of oral drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome).
- Clinically significant, uncontrolled heart disease (including history of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality within 12 months of screening).
- Known active viral hepatitis or known human immunodeficiency virus (HIV) infection or any other uncontrolled infection.
- Presence of any NCI-CTCAE v5 grade ≥ 2 treatment-related extra-hematological toxicity with the exception of alopecia, ototoxicity or peripheral neuropathy.
- Known congenital immunodeficiency.
- Radiotherapy within the 2 months preceding D1 of the start of study treatment. Palliative RT on a non-target lesion is allowed up to 1 weeks before beginning of treatment.
- Major surgery within 21 days of the first dose. Gastrostomy, ventriculo-peritoneal shunt, endoscopic ventriculostomy, tumor biopsy and insertion of central venous access devices are not considered major surgery, but for these procedures, a 48 hour interval must be maintained before the first dose of the investigational drug is administered.
- Bleeding disorder.
- Clinically significant, uncontrolled heart disease (including history of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality within 12 months of screening).
- Known hypersensitivity to any study drug or component of the formulation.
- Absence of effective contraception in patients of childbearing age (see appendix 3)
- Pregnant or nursing (lactating) females.
- Patients with galactose intolerance, lactase deficiency or glucose or galactose malabsorption syndrome (rare hereditary diseases).
- Severe infections requiring parenteral antibiotic therapy.
- Inability to undergo medical monitoring of the trial for geographic, social or psychological reasons.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Patients receiving axitinib in combination with etoposide
|
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Dose-limiting toxicity (DLT)
Lasso di tempo: During the first 28 days (cycle 1)
|
During first stage |
During the first 28 days (cycle 1)
|
|
Progression-free survival (PFS)
Lasso di tempo: 3 years (from start of treatment to last follow-up visit)
|
During second stage, progression-free survival (PFS) computed as the time interval from the beginning of treatment to the date of centrally-assessed with RAPNO criteria. A central review of all imaging is planned at the end of phase 1 and at the end of phase expansion to evaluate tumor response and progressions. PFS-duration of patients alive free of progression at last follow-up will be censored at the date of last visit. |
3 years (from start of treatment to last follow-up visit)
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Nicolas ANDRE, Assistance Publique - Hôpitaux de Marseille
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie
- Neoplasie per tipo istologico
- Neoplasie, ghiandolari ed epiteliali
- Glioma
- Neoplasie, Neuroepiteliali
- Tumori neuroectodermici
- Neoplasie, cellule germinali ed embrionali
- Neoplasie, tessuto nervoso
- Tumori neuroectodermici, primitivi
- Ependimoma
- Medulloblastoma
- Prodotti chimici organici
- Idrocarburi
- Idrocarburi, ciclici
- Carboidrati
- Podofillotossina
- Tetraidonaftalene
- Naftalene
- Idrocarburi policiclici aromatici
- Idrocarburi, aromatici
- Composti policiclici
- Glucosidi
- Glicosidi
- Etoposide
Altri numeri di identificazione dello studio
- RCAPHM23_0164
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .